

Epidemiology of *Aspergillus terreus* at a University Hospital

John W. Baddley,^{1*} Peter G. Pappas,¹ Anita C. Smith,² and Stephen A. Moser²

Department of Medicine, Division of Infectious Diseases,¹ and Department of Pathology,²
University of Alabama at Birmingham, Birmingham, Alabama

Received 14 May 2003/Returned for modification 7 July 2003/Accepted 20 September 2003

Invasive fungal infections due to *Aspergillus* species have become a major cause of morbidity and mortality among immunocompromised patients. *Aspergillus terreus*, a less common pathogen, appears to be an emerging cause of infection at our institution, the University of Alabama hospital in Birmingham. We therefore investigated the epidemiology of *A. terreus* over the past 6 years by using culture data; antifungal susceptibility testing with amphotericin B, voriconazole, and itraconazole; and molecular typing with random amplification of polymorphic DNA-PCR (RAPD-PCR). During the study period, the percentage of *A. terreus* isolates relative to those of other *Aspergillus* species significantly increased, and *A. terreus* isolates frequently were resistant to amphotericin B. Molecular typing with the RAPD technique was useful in discriminating between patient isolates, which showed much strain diversity. Further surveillance of *A. terreus* may better define epidemiology and determine whether this organism is becoming more frequent in relation to other *Aspergillus* species.

Invasive fungal infections due to *Aspergillus* species have become a major cause of morbidity and mortality among immunocompromised patients. *Aspergillus fumigatus* is most frequently isolated from clinical specimens, but other important species include *A. flavus*, *A. niger*, and *A. terreus*. *A. terreus* appears to be emerging as a cause of opportunistic infections (8, 9, 20) and is of concern because of in vitro resistance to amphotericin B (18). At our institution, the University of Alabama hospital in Birmingham, an increase in the frequency of *A. terreus* isolates and invasive infections due to *A. terreus* has been noticed (4). Although several recent studies have discussed clinical cases of invasive *A. terreus* disease and strain typing of *A. terreus* environmental and clinical isolates (7, 9, 11, 19, 20), questions about the epidemiology of *A. terreus* remain unanswered. We therefore were interested in studying the epidemiology of *A. terreus* at our tertiary care university hospital with the use of clinical data, antifungal susceptibility testing, and molecular genotyping using the random amplification of polymorphic DNA-PCR (RAPD-PCR) method.

(This work was presented in part at the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, Ill., 16 to 19 December 2001.)

MATERIALS AND METHODS

We identified cultures positive for *A. terreus* and other *Aspergillus* species at the laboratory of the University of Alabama hospital over a 6-year period (1996 to 2001) to investigate the frequency of isolation of *A. terreus* from clinical samples. The Laboratory Information System was utilized to identify the number of *Aspergillus* isolates. A subgroup of 41 patients with cultures positive for *A. terreus* was selected for a more focused epidemiologic study that included medical record review. In addition, 23 of 41 patients had isolates stored and available for molecular typing and susceptibility testing. Data collected from medical records included demographics, information on underlying disease, identification of the clinical disease entity or condition due to *A. terreus* (invasive aspergillosis, chronic necrotizing pneumonia [semi-invasive aspergillosis], aspergilloma, aller-

gic bronchopulmonary aspergillosis, colonization, or contamination), and dates and sources of cultures positive for *A. terreus*. Colonization was defined as having a culture positive for *A. terreus* without evidence of clinical or histopathologic disease. Contamination was defined as isolation of *Aspergillus* but no apparent connection with clinical condition or relevance to the patient (15). Invasive infection was defined as the recovery of *A. terreus* from a sterile site or a biopsy specimen or from a contiguous nonsterile site with compatible clinical and radiographic findings. Chronic necrotizing pneumonia, aspergilloma, and allergic bronchopulmonary aspergillosis were classified on the basis of current guidelines (16). Patient locations at the time of culture, dates of hospital admission and discharge, and locations within the hospital throughout hospital stays were determined for 23 patients whose isolates were available for typing in order to investigate potential clustering of cases or a potential hospital source of isolates. Strain relatedness was determined by molecular genotyping with the use of RAPD-PCR. Antifungal susceptibility of *A. terreus* isolates to amphotericin B, itraconazole, and voriconazole was determined.

Molecular genotyping. Twenty-three clinical isolates from twenty-three patients were subjected to molecular genotyping. Reactions were carried out three times to confirm reproducibility. In brief, isolates were grown on Sabouraud's dextrose agar slants and spores were harvested and inoculated into Vogel's medium at a final concentration of 10^7 spores/ml before incubation at 37°C for 48 h. Mycelium collected by filtration was freeze-dried with liquid nitrogen, ground to a powder, and added to microcentrifuge tubes. After centrifugation, the pellets were resuspended in extraction buffer (2, 5). DNA was isolated by heating in a boiling water bath, extracting once with chloroform-isoamyl alcohol (1:1) and twice with isopropanol, and precipitating with ethanol. RAPD-PCR was performed using 100 ng of *A. terreus* DNA as a template, primers R108 (GTATTGCCCT; 50% G+C content) and CII (GCGCACGG; 88% G+C content) obtained from Oligos, Etc., Portland, Oreg., and Stoffel DNA polymerase in a Perkin-Elmer model 480 thermocycler (Perkin-Elmer, Norwalk, Conn.) (3). The following conditions were used: 1 cycle of 94°C for 5 min, 30°C for 1 min, and 72°C for 1 min; 35 cycles of 94°C for 1 min, 36°C for 1 min, and 72°C for 1 min; 5 cycles of 94°C for 1 min, 36°C for 1 min, and 72°C for 5 min; and then refrigeration at 4°C (2). Aliquots of PCR products were analyzed by electrophoresis in a 1.5% agarose gel with ethidium bromide at 0.5 µg/ml and photographed under UV light (GelDoc 2000; Bio-Rad). Analysis of the DNA band patterns was done with Gelcompar II software (Applied Maths, Kortrijk, Belgium). Highly related strains (groups) were defined as those having at least 90% homology on the basis of banding patterns.

Antifungal susceptibility testing. (i) Organisms. A total of 23 *A. terreus* isolates from 23 patients were available for antifungal susceptibility testing. Sources of isolates included 22 respiratory specimens (sputum, bronchoalveolar lavage fluid, transbronchial biopsy specimen, or tracheal aspirate) and 1 wound specimen. Isolates were grown on potato flake agar and identified as *A. terreus* by colony color and typical microscopic morphology, including the presence of aleuriospores (17). All isolates were grown on potato flake agar slants and stored at –70°C until testing.

* Corresponding author. Mailing address: University of Alabama at Birmingham, Department of Medicine, Division of Infectious Diseases, 1900 University Blvd., 229 Tinsley Harrison Tower, Birmingham, AL 35294-0006. Phone: (205) 934-5191. Fax: (205) 934-5155. E-mail: jbaddley@uab.edu.




FIG. 1. Graph depicting the frequency of isolation of *A. terreus* isolates relative to that of all *Aspergillus* species during the study period (black bars) and the percentage of patients with *A. terreus* isolates relative to the total number of patients with *Aspergillus* species (white bars). Total numbers of *Aspergillus* isolates are listed below the x axis. The y axis represents percentages of *A. terreus* isolates or patients.

(ii) **Antifungal drugs.** Voriconazole (Pfizer Pharmaceutical Group, New York, N.Y.), itraconazole (Janssen Research Foundation, Beerse, Belgium), and amphotericin B (Sigma Chemical Co., St. Louis, Mo.) were obtained as reagent-grade powders from their manufacturers, and stock solutions were prepared in dimethyl sulfoxide. All drugs were diluted in RPMI 1640 medium (Sigma Chemical Co.) buffered to pH 7.0 with morpholinepropanesulfonic acid (MOPS) buffer and dispensed into 96-well microdilution trays. Trays containing an aliquot of 0.1 ml of appropriate drug solution ($2\times$ final concentration) in each well were sealed and stored at -70°C until use. The final ranges of drug concentrations tested were 0.008 to 8 $\mu\text{g}/\text{ml}$ for voriconazole and itraconazole and 0.016 to 16 $\mu\text{g}/\text{ml}$ for amphotericin B.

(iii) **Susceptibility testing.** MICs were determined by NCCLS M38-A broth microdilution methodology (13). In brief, isolates were grown on potato dextrose agar slants at 35°C for 7 days. The slants were covered with 1 ml of sterile 85% saline and gently scraped with a sterile pipette. The resulting suspensions were transferred to separate tubes, and heavy particles were allowed to settle. Turbidities of the conidial suspensions were measured at 530 nm and adjusted to optical densities ranging from 0.09 to 0.11 (80 to 82% transmittance). Final concentrations of stock inocula ranged from 0.5 to 5×10^6 CFU/ml and were verified by plating onto Sabouraud dextrose agar. Drug-free controls were included in each tray. The microdilution trays were incubated at 35°C for 48 h. Following incubation, MIC endpoints were determined as the lowest drug concentrations that prevented any discernible growth (optically clear) compared to that of the drug-free controls. Quality control was measured by inclusion of the following strains: *Candida parapsilosis* (ATCC 22019) and *C. krusei* (ATCC 6258). All readings were within the recommended limits based on NCCLS M38-A methodology (13).

RESULTS

Eight hundred sixty-nine *Aspergillus* isolates were identified by the University of Alabama at Birmingham Clinical Microbiology Laboratory during the 6-year study period. The most common species was *A. fumigatus*, making up 60% of isolates, followed by *A. niger* (18%), *A. terreus* (12%), and *A. flavus* (9%). One hundred seven isolates of *A. terreus* from 41 patients were identified (1 isolate from 1 patient, 1996; 4 isolates from 2 patients, 1997; 19 isolates from 2 patients, 1998; 23 isolates from 6 patients, 1999; 31 isolates from 19 patients, 2000; and 29 isolates from 11 patients, 2001). As shown in Fig. 1, the percentage of *A. terreus* isolates relative to the total number of *Aspergillus* isolates (1.5% in 1996 to 15.4% in 2001; $P < 0.001$; chi-square test for linear trend [EPI-INFO 6]) and the percentage of patients with *A. terreus* isolates relative to the total

TABLE 1. Results of RAPD typing of *A. terreus* isolates

Date (mo/day/yr) of isolation	Patient no.	R108-identified type ^a	CII-identified type ^a	Combined type ^b
5/26/96	1	M	A	I
2/26/97	2	O	E	II
2/26/97	6	L	E	III
7/3/97	22	I	C	IV
4/03/98	7	Q	J	V
11/20/98	8	P	B	VI
2/27/99	9	K	F	VII
3/12/99	10	N	F	VIII
11/5/99	3	C	I	IX
1/10/00	4	L	E	III
1/20/00	5	K	E	X
8/5/00	11	E	D	XI
9/7/00	19	A	G	XII
9/11/00	20	G	C	XIII
10/3/00	16	A	H	XIV
10/9/00	17	F	D	XV
10/11/00	18	A	G	XII
10/25/00	12	B	D	XVI
11/10/00	13	H	D	XVII
12/6/00	15	J	K	XVIII
12/7/00	21	D	L	XIX
12/23/00	23	A	G	XII
1/29/01	14	D	L	XIX
Total no. of types		17	12	19

^a Refers to RAPD type determined with the use of the R108 or CII primer (Fig. 2 and 3).

^b Results of the combined analysis of RAPD types produced by primers R108 and CII.

number of patients with *Aspergillus* isolates (2.1% in 1996 to 10.2% in 2001; $P = 0.001$) significantly increased during the study period.

Clinical data were collected from 41 patients with positive *A. terreus* cultures. Isolates from 34 (83%) of 41 patients were cultured from the respiratory tract, those from three patients (7.3%) were from skin and soft tissues, and isolates from one patient each were from blood, a toenail, the ear canal, and peritoneal fluid. The mean age of patients was 54 years, and 66% were male. Twenty (48.7%) of 41 patients were immunocompromised, with 11 (26.8%) having received solid organ or hematopoietic stem cell transplants. Twenty-four (58.5%) of 41 patients were colonized with *A. terreus*, and in three patients (7.3%), isolates were considered to be contaminants. Of 14 patients (34%) with infection, 11 had invasive aspergillosis, 1 had aspergilloma, 1 had external otitis, and 1 had onychomycosis. Among the 11 patients with invasive aspergillosis, 5 (45.4%) had disseminated disease and the deaths of 8 patients (72.7%) were attributed to *A. terreus* infection. Throughout the study period, among patients who had typing data available, there appeared to be time-related clusters of hospitalized patients with positive *A. terreus* cultures (Table 1); however, these patients were not consistently located in the same hospital units or areas.

Antifungal susceptibilities. The activities of amphotericin B, itraconazole, and voriconazole against 23 patient isolates of *A. terreus* are shown in Table 2. Itraconazole and voriconazole were highly active against *A. terreus* (100% susceptible at an MIC of ≤ 1 $\mu\text{g}/\text{ml}$), while only 13% of isolates were susceptible to amphotericin B at an MIC of ≤ 1 $\mu\text{g}/\text{ml}$.

TABLE 2. In vitro susceptibilities of 23 isolates of *A. terreus* to amphotericin B, itraconazole, and voriconazole

Antifungal agent	MIC (μg/ml) ^a			% of isolates susceptible at an MIC (μg/ml) of:				
	Range	50%	90%	0.25	0.5	1	2	4
Amphotericin B	1–4	2	4	0	0	13	87	100
Itraconazole	0.06–1	0.5	1	48	83	100	100	100
Voriconazole	0.25–1	0.5	0.5	30	96	100	100	100

^a 50% and 90%, MICs at which 50 and 90% of isolates are inhibited, respectively.

Molecular genotyping. Twenty-three isolates from 23 patients were genotyped using RAPD-PCR methodology with two primers previously shown to have good discriminatory power for *Aspergillus* species (2, 5). Seventeen distinct strains were identified with the R108 primer (Fig. 2) and 12 distinct strains were identified with the CII primer (Fig. 3). By combining the results of the two primers, 19 distinct strains were identified (Table 1).

Several patients' isolates were highly similar (>90% homology) and were placed in three groupings: type III (patients 4 and 6), type XII (patients 18, 19, and 23), and type XIX

(patients 14 and 21). Patients 4 and 6 were hospitalized and their specimens were cultured almost 3 years apart (Table 1). Patients 18, 19, and 23 had *A. terreus* cultures that were temporally related, but they were not hospitalized at the same time nor were they in the same ward or unit. Patients 14 and 21 were hospitalized at the same time but were in different locations.

DISCUSSION

Our study confirms that *A. terreus* is an increasingly common clinical isolate, but our data also do not support a common




FIG. 2. Dendrogram and gel band patterns of RAPD fingerprints of 23 *A. terreus* isolates typed with primer R108. The scale at the top represents percent similarity. The patient numbers and strain types are listed to the right of the figure and correspond to those in Table 1.




FIG. 3. Dendrogram and gel band patterns of RAPD fingerprints of 23 *A. terreus* isolates typed with primer CII. The scale at the top represents percent similarity. The patient numbers and strain types are listed to the right of the figure and correspond to those in Table 1.

source for this phenomenon. At our institution, *A. terreus* appears to be an emerging pathogen and constitutes a growing proportion of *Aspergillus* isolates in our hospital over the last several years. By comparison, in a recent 1-year, multicenter epidemiologic survey in the United States, of 1,477 *Aspergillus* isolates, only 17 (1%) were *A. terreus* (15). Chandrasekar and colleagues have reported an increase in *Aspergillus* species over the past decade, but the number of *A. terreus* isolates did not appear to increase during the study period (6). Recent surveillance data from other institutions would be helpful to determine whether our observed trend over the past 6 years is representative of trends at other sites.

In parallel with the increased number of clinical isolates, there has been a growing number of patients with invasive disease caused by *A. terreus* at our institution, especially among immunocompromised patients (4). Of 41 patients with positive cultures, nearly one-half were immunocompromised, and 11 (27%) of 41 had invasive infection. Of the 11 patients with invasive disease, 8 died of the infection with disseminated disease or overwhelming pneumonia. Perfect and colleagues reported that among 17 patients with *A. terreus* isolates, inva-

sive disease was seen in 47% (15). Other recent reports have found that between 3 and 13% of cases of invasive aspergillosis may be due to *A. terreus* and that disease is rapidly progressive in immunocompromised patients (9, 20). Therefore, an isolate of *A. terreus* from an immunocompromised patient is of concern and should be considered a potential pathogen.

In isolates we studied, as has been previously reported, MICs of amphotericin B were higher for *A. terreus* than for *A. fumigatus* (18). Amphotericin B resistance may in part explain the rapid disease progression and poor clinical response seen among some patients, as until recently amphotericin B had been considered standard primary treatment for invasive aspergillosis (16). MICs of voriconazole and itraconazole for *A. terreus* isolates were similar to those in other reports (17, 18).

The molecular genotyping of *Aspergillus* species has proven useful in many epidemiologic situations (11, 12, 19). One of the most widely used genotyping techniques is RAPD-PCR, a relatively technically simple and rapid procedure. Although RAPD-PCR has been criticized for a lack of reproducibility, this method has been used with success for *A. terreus* isolates (5, 19). Birch and Denning used five primers to test 14 isolates

and found primers R108 and CII to be highly discriminatory (5). Symoens and colleagues tested 43 isolates of environmental and clinical origins with the primers NS3 and NS7 (19). Among epidemiologically unrelated isolates, the primers were highly discriminatory. In addition, they found RAPD-PCR to be a useful tool in demonstrating the clonal origin of contamination of the environment in a hematology unit. Among our patients, each primer was highly discriminatory, and when the primers were used in combination, 19 different strains were found. Three groups of patients had highly related ($\geq 90\%$ homology) strains, but only two patients in one group were hospitalized at the same time. Moreover, the patients were in different hospital locations during their stay. No common exposures could be detected to suggest nosocomial acquisition; however, certain factors present may not have been identified in the chart review. Environmental isolates were not obtained during the study period but may have been useful in identifying potential nosocomial exposures.

It remains unclear why the frequencies of *A. terreus* isolates and infections are increasing at our institution. Multiple studies have linked hospital construction and renovation to *Aspergillus* species outbreaks (7, 10, 14). Hospital construction has been prevalent at our institution over the past decade but not in areas where these patients were housed. Lass-Flörl and colleagues suggested potted plants as a source of *A. terreus*, and there are also concerns about *Aspergillus* species contaminating water and foodstuffs (1, 11). It is important that targeted surveillance of *Aspergillus* species, especially *A. terreus*, be continued in order to better define environmental patterns.

In conclusion, *A. terreus* has become more common at our institution over the past 6 years. It is an important pathogen because of relative amphotericin B resistance and the potential to cause rapidly progressive invasive infections in immunocompromised patients. Molecular genotyping of isolates with RAPD-PCR was helpful in discriminating patient isolates, and when results of this procedure are combined with other clinical and epidemiologic data, it appears that *A. terreus* isolates at our institution are highly diverse and are unlikely to come from a common source. Surveillance of *A. terreus* at other institutions may be helpful to better define epidemiology and determine whether this organism is becoming more frequent in relation to other *Aspergillus* species.

REFERENCES

1. Anaissie, E. J., and S. F. Costa. 2001. Nosocomial aspergillosis is waterborne. *Clin. Infect. Dis.* **33**:1546–1548.
2. Anderson, M. J., K. Gull, and D. W. Denning. 1996. Molecular typing by random amplification of polymorphic DNA and M13 Southern hybridization of related paired isolates of *Aspergillus fumigatus*. *J. Clin. Microbiol.* **34**:87–93.
3. Aufauvre-Brown, A., J. Cohen, and D. W. Holden. 1992. Use of randomly amplified polymorphic DNA markers to distinguish isolates of *Aspergillus fumigatus*. *J. Clin. Microbiol.* **30**:2991–2993.
4. Baddley, J. W., T. A. Stroud, D. Salzman, and P. G. Pappas. 2001. Invasive mold infections in allogeneic bone marrow transplant recipients. *Clin. Infect. Dis.* **32**:319–324.
5. Birch, M., and D. W. Denning. 1999. Molecular typing of *Aspergillus terreus* by random amplification of polymorphic DNA. *Eur. J. Clin. Microbiol. Infect. Dis.* **18**:838–841.
6. Chandrasekar, P. H., J. L. Cutright, and E. K. Manavathu. 2001. Aspergillosis: rising frequency of clinical isolation and continued susceptibility to antifungal agents, 1994–1999. *Diagn. Microbiol. Infect. Dis.* **41**:211–214.
7. Flynn, P. M., B. G. Williams, S. V. Hetherington, B. F. Williams, M. A. Giannini, and T. A. Pearson. 1993. *Aspergillus terreus* during hospital renovation. *Infect. Control Hosp. Epidemiol.* **14**:363–365.
8. Hara, K. S., J. H. Ryu, J. T. Lie, and G. D. Roberts. 1989. Disseminated *Aspergillus terreus* infection in immunocompromised hosts. *Mayo Clin. Proc.* **64**:770–775.
9. Iwen, P. C., M. E. Rupp, A. N. Langnas, E. C. Reed, and S. H. Hinrichs. 1998. Invasive pulmonary aspergillosis due to *Aspergillus terreus*: 12-year experience and review of the literature. *Clin. Infect. Dis.* **26**:1092–1097.
10. Krasinski, K., R. S. Holzman, B. Hanna, M. A. Greco, M. Graff, and M. Bhogal. 1985. Nosocomial fungal infection during hospital renovation. *Infect. Control* **6**:278–282.
11. Lass-Flörl, C., P. Rath, D. Niederwieser, G. Kofler, R. Würzner, A. Krezy, and M. P. Dierich. 2000. *Aspergillus terreus* infections in haematological malignancies: molecular epidemiology suggests association with in-hospital plants. *J. Hosp. Infect.* **46**:31–35.
12. Leenders, A., A. van Belkum, S. Janssen, S. de Marie, J. Kluytmans, J. Wielenga, B. Lowenberg, and H. Verbrugh. 1996. Molecular epidemiology of apparent outbreak of invasive aspergillosis in a hematology ward. *J. Clin. Microbiol.* **34**:345–351.
13. National Committee for Clinical Laboratory Standards. 2002. Reference method for broth dilution antifungal susceptibility testing of filamentous fungi. Approved standard M38-A. National Committee for Clinical Laboratory Standards, Wayne, Pa.
14. Oren, I., N. Haddad, R. Finkelstein, and J. M. Rowe. 2001. Invasive pulmonary aspergillosis in neutropenic patients during hospital construction: before and after chemoprophylaxis and institution of HEPA filters. *Am. J. Hematol.* **66**:257–262.
15. Perfect, J. R., G. M. Cox, J. Y. Lee, C. A. Kauffman, L. de Repentigny, S. W. Chapman, V. A. Morrison, P. G. Pappas, J. W. Hiemenz, D. A. Stevens, and the Mycoses Study Group. 2001. The impact of culture isolation of *Aspergillus* species: a hospital based survey of aspergillosis. *Clin. Infect. Dis.* **33**:1824–1833.
16. Stevens, D. A., V. L. Kan, M. A. Judson, V. A. Morrison, S. D. Dummer, D. W. Denning, J. E. Bennett, T. J. Walsh, T. F. Patterson, and G. A. Pankey. 2000. Practice guidelines for disease caused by *Aspergillus*. *Clin. Infect. Dis.* **30**:696–709.
17. Sutton, D. A., A. W. Fothergill, and M. G. Rinaldi. 1998. Guide to clinically significant fungi. Williams & Wilkins, Baltimore, Md.
18. Sutton, D. A., S. E. Sanche, S. G. Revankar, et al. 1999. In vitro amphotericin B resistance in clinical isolates of *Aspergillus terreus*, with a head-to-head comparison to voriconazole. *J. Clin. Microbiol.* **37**:2343–2345.
19. Symoens, F., J. P. Bouchara, S. Heinemann, and N. Nold. 2000. Molecular typing of *Aspergillus terreus* isolates by random amplification of polymorphic DNA. *J. Hosp. Infect.* **44**:273–280.
20. Tritz, D. M., and G. L. Woods. 1993. Fatal disseminated infection with *Aspergillus terreus* in immunocompromised hosts. *Clin. Infect. Dis.* **16**:118–122.